JMC Annotation Spotlight: Analysis of Breakthrough Therapeutics

This report features four highly representative and innovative therapeutics recently profiled in the JMC Annotation column (submitted before December 2024 and with no clinical failure reported to date). The selection spans a diverse range of modalities, including covalent inhibitors, receptor-selective agonists, and CNS-penetrant compounds. The drugs are being developed by leading pharmaceutical and biotech companies such as Chiesi Farmaceutici S.p.A., Galapagos, Scorpion Therapeutics, and AstraZeneca.Through a systematic examination of the R&D paths of these compounds, this report aims to uncover their therapeutic potential, while also offering insight into their commercial prospects and developmental challenges.